ArticleBrain : a journal of neurology2011
Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography.
Article in Brain : a journal of neurology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.Movement disorders : official journal of the Movement Disorder Society · 2015Pooled it
- Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2013Guideline
- Sink-index: a network-based EEG marker for frontotemporal dementia and Alzheimer's disease.Brain communications · 2025Article
- Cortical Thickness and Brain Glucose Metabolism in Healthy Aging.Journal of clinical neurology (Seoul, Korea) · 2023Article
- Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer's Disease or Dementia with Lewy Bodies.Journal of Alzheimer's disease : JAD · 2021Article
- Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC).EJNMMI radiopharmacy and chemistry · 2020Article
- Case Report: The Role of Neuropsychological Assessment and Imaging Biomarkers in the Early Diagnosis of Lewy Body Dementia in a Patient With Major Depression and Prolonged Alcohol and Benzodiazepine Dependence.Frontiers in psychiatry · 2020Article
- Neuroimaging in Lewy body dementia.Journal of neurology · 2019Review
- Agreement among neuropsychological and behavioral data and PiB findings in diagnosing Frontotemporal Dementia.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2017Article
- Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias.Current neurology and neuroscience reports · 2017Review
- Post-Mortem evaluation of amyloid-dopamine terminal positron emission tomography dementia classifications.Annals of neurology · 2015Article
- Imaging Amyloidopathy in Parkinson Disease and Parkinsonian Dementia Syndromes.Clinical and translational imaging · 2015Article
- Imaging the role of amyloid in PD dementia and dementia with Lewy bodies.Current neurology and neuroscience reports · 2014Review
- PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.BMC neurology · 2014Article
- Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2013Article
- C9ORF72 expansion in a family with bipolar disorder.Bipolar disorders · 2013Article
- Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia.Neurology · 2012Article
- The development, past achievements, and future directions of brain PET.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2012Review
- An update on brain imaging in parkinsonian dementia.Imaging in medicine · 2012Article
- Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications.Alzheimer's research & therapy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
We assessed the relationship between consensus clinical diagnostic classification and neurochemical positron emission tomography imaging of striatal vesicular monoamine transporters and cerebrocortical deposition of aβ-amyloid in mild dementia. Seventy-five subjects with mild dementia (Mini-Mental State Examination score≥18) underwent a conventional clinical evaluation followed by 11C-dihydrotetrabenazine positron emission tomography imaging of striatal vesicular monoamine transporters and 11C-Pittsburgh compound-B positron emission tomography imaging of cerebrocortical aβ-amyloid deposition. Clinical classifications were assigned by consensus of an experienced clinician panel. Neuroimaging classifications were assigned as Alzheimer's disease, frontotemporal dementia or dementia with Lewy bodies on the basis of the combined 11C-dihydrotetrabenazine and 11C-Pittsburgh compound-B results. Thirty-six subjects were classified clinically as having Alzheimer's disease, 25 as having frontotemporal dementia and 14 as having dementia with Lewy bodies. Forty-seven subjects were classified by positron emission tomography neuroimaging as having Alzheimer's disease, 15 as having dementia with Lewy bodies and 13 as having frontotemporal dementia. There was only moderate agreement between clinical consensus and neuroimaging classifications across all dementia subtypes, with discordant classifications in ∼35% of subjects (Cohen's κ=0.39). Discordant classifications were least frequent in clinical consensus Alzheimer's disease (17%), followed by dementia with Lewy bodies (29%) and were most common in frontotemporal dementia (64%). Accurate clinical classification of mild neurodegenerative dementia is challenging. Though additional post-mortem correlations are required, positron emission tomography imaging likely distinguishes subgroups corresponding to neurochemically defined pathologies. Use of these positron emission tomography imaging methods may augment clinical classifications and allow selection of more uniform subject groups in disease-modifying therapeutic trials and other prospective research involving subjects in the early stages of dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.